Lymphoma, T-Cell - 42 Studies Found
| Completed |
: A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma : Lymphoma, T-Cell, Peripheral : 2005-09-13 : Drug: ONTAK (denileukin diftitox, DAB389 IL-2) Ontak + CHOP every 3 weeks. |
| No longer available |
: Compassionate Use of Vorinostat for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma (0683-042) : Lymphoma, T-Cell, Cutaneous : 2007-01-05 : Drug: Comparator: vorinostat Each patient will receive open-label vorinostat 400 mg q.d. capsules. Treat |
| Completed |
: Intensive Chemo-immunotherapy as First Line Treatment in Adult Patients With Peripheral T- Cell Lymphoma : Lymphoma, T-Cell, Peripheral : 2012-08-30 :
|
| Completed |
: A Retrospective Study of Clinical, Phenotypic and Genetic Factors of Peripheral T-Cell Lymphomas : Lymphoma, T-Cell, Peripheral : 2016-05-23 : Other: No Intervention |
| Active, not recruiting |
: A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL) : Lymphoma, T-cell, Peripheral : 2011-10-18 : Drug: Romidepsin Intravenous dosing for 4 hours on Days 1, 8, and 15 of each 28-day cycle |
| Terminated |
: LAMPP Trial for Peripheral and Cutaneous T-Cell Lymphoma : T-Cell Lymphoma : 2005-09-08 : Drug: Doxil, Methotrexate, L-Asparaginase, Prednisone |
| Completed |
: A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients : T Cell Lymphoma : 2012-03-13 : Drug: Sorafenib Intrapatient dose reduction to 400 mg once daily and then 400 mg every other day will be |
| Completed |
: Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma : T-cell Lymphoma : 2009-08-14 : Drug: Bendamustine Bendamustine at the dose of 120 mg/m2 IV over 60 minutes on days 1 and 2 every 21 day |
| Completed |
: Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma : T Cell Lymphoma : 2008-11-21 : Drug: Fostamatinib Disodium 200 mg PO BID Other Name |
| Recruiting |
: Study of MK-3475 in Relapsed or Refractory Peripheral T-cell Non-Hodgkin Lymphoma : Lymphoma, T-Cell, Peripheral : 2015-08-26 : Drug: MK-3475 Other Name: Pembrolizumab |